PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer
Title: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast CancerBackground: The advent of subtype-specific treatments, particularly hormone therapies and HER2-targeted therapies, has significantly improved survival rates and quality of life for breast cancer (BC) patients. Over the last decade genomic signatures have enabled improved classification Read More
MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX Background: For patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer (EBC), pathological Complete Response (pCR) rates to neoadjuvant chemotherapy (NCT) are low. However, NBRST and I-SPY2 trials report Read More
Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine- Biology is Still King
Title: Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine- Biology is Still King Authors: Rakhshanda Rahman, Christin Collins*, Laura Lee, Alfredo Santillan, Mehran Habibi, Peter Blumencranz, Charlie Cox, James Pellicane, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy *Presenting Author Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Title: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data Authors: Adam Brufsky*, Kent Hoskins, Henry Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman, Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Title: Association of MammaPrint® With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become a first-line targeted treatment in combination with endocrine therapy for patients with recurring HR+HER2- breast cancer (BC) and have recently been added to the Read More
Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Title: Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjöld, G. Read More
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
Title: Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van ’t Veer, PhD; Elma Meershoek-Klein Kranenbarg, MS; Marjolijn Duijm-de Carpentier, BS; Cornelis J. H. Van de Velde, MD; Miranda Read More
